The BCTRIMS Expanded Consensus on treatment of multiple sclerosis: III. Evidence and recommendation-based guidelines;Consenso Expandido do BCTRIMS para o tratamento da esclerose múltipla: III. Diretrizes baseadas em evidências e recomendações

Arquivos de Neuro-Psiquiatria

Volumn 60, Issue 3 B, 2002, Pages 881-886

  Lana Peixoto, Marco Aurélio ^a   Callegaro, Dagoberte ^a   Moreira, Marcos Aurélio ^a   Campos, Gilberto Belisário ^a   Marchiori, Paulo Eurípedes ^a   Gabbai, Alberto Alain ^a   Bacheschi, Luiz Alberto ^a   Arruda, Walter Oleschko ^a   Gama, Paulo Diniz Da ^a   Melo, Aílton Souza ^a   Rocha, Fernando Coronetti Gomes Da ^a   Lino, Angelina Maria Martins ^a   Ferreira, Maria Lúcia Brito ^a   Júnior, Luiz Ataíde ^a  

^a NONE

Author keywords

Immunointervention; Multiple sclerosis; Recommendation; Treatment

Indexed keywords

AZATHIOPRINE; BETA1A INTERFERON; CORTICOSTEROID; CORTICOTROPIN; CYCLOPHOSPHAMIDE; GLATIRAMER; HUMAN IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INTERFERON BETA SERINE; METHOTREXATE; MITOXANTRONE;

AUTOLOGOUS BONE MARROW TRANSPLANTATION; BRAZIL; CLINICAL TRIAL; DEPRESSION; DEVELOPING COUNTRY; DRUG COST; DRUG INDICATION; DRUG SURVEILLANCE PROGRAM; EVIDENCE BASED MEDICINE; FLU LIKE SYNDROME; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INDIVIDUALIZATION; INFORMED CONSENT; LYMPHOCYTOPENIA; MEDICAL SOCIETY; MODEL; MULTIPLE SCLEROSIS; PATIENT EDUCATION; PLASMAPHERESIS; PRACTICE GUIDELINE; PUBLICATION; REVIEW; RISK BENEFIT ANALYSIS; SKIN MANIFESTATION; SPASTICITY; SUICIDE;

EID: 0344555407     PISSN: 0004282X     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0004-282x2002000500037     Document Type: Review

References (28)

1. Tilbery CP, Moreira MA, Mendes MF, Lana-Peixoto MA and The Brazilian Committee for Treatment and Research in Multiple Sclerosis - BCTRIMS. Recomendações quanto ao uso de drogas imunomoduladoras na esclerose múltipla. Arq Neuropsiquiatr 2000;58:769-776.
2. Societé Française de Neurologie. Conference de Consensus sur la Sclérose en Plaques. Rev Neurol (Paris) 2001;157:902-1192.
3. Goodin DS, Frohman EM, Garmany GPJr, et al. Disease modifying therapies in multiple sclerosis: Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002;58:169-178.
4. Freedman MS, Blunhardt LD, Brochet B, et al. International consensus on the use of disease-modifying agents in multiple sclerosis. Multiple Sclerosis 2002;8:19-23.
5. Secretaria de Assistência à Saüde, Ministério da Saúde. Portarias nos 97 e 98. Diário Oficial da União 23 de março de 2001.
6. Cook DJ, Guyatt GH, Laupacis A, Sackett DL. Rules of evidence and clinical recommendation on the use of antithrombotic agents. Chest 1992;102 (Suppl 4):3055-3115.
7. Report of the Quality standards Subcommittee. Practice advisory on selection of patients with multiple sclerosis for treatment with betaferon. Neurology 1994;44:1537-1540.
8. WHO Working Group in Multiple sclerosis. Multiple sclerosis and public health: education and management implications. Geneva: World Health Organization, 1999:6-11.
9. Callegaro D, Goldbaum M,Morais L, et al. the prevalence of multiple sclerosis in the city of São Paulo, Brasil, 1997. Acta Neurol Scand 2001;104:208-213.
10. Lana-Peixoto MA, Frota ERC, Campos GB, Botelho CM, Aragão AL, Monteiro L. The prevalence of multiple sclerosis in Belo Horizonte, Brazil. Multiple Sclerosis. Submetido para publicação.
11. Whetten-Goldstein K, Sloan F, Conover C, Viscusi K, Kulas B, Chesson H. The economic burden of multiple sclerosis. MS Management 1996;3:33-338.
12. Poser CM, Paty DW, Scheinberg LC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231.
13. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001;50:121-127.
14. Barkhof F, Fillippi M, Miller DH, et al. Comparison of MR imaging criteria and first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997;120:2059-2064.
15. Tintoré M, Rovira M, Martinez MJ, et al. Isolated demyelinating syndromes; comparisons of different MRI imaging criteria to predict conversion to clinically definite multiple sclerosis. Am J Neuroradil 2000;21:702-706.
16. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey.. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical trials of New Agents in Multiple sclerosis. Neurology 1996;46:907-911.
17. Miller H, Newell DJ, Ridley A. Multiple sclerosis: treatment of acute exacerbations with corticotrophin (ACTH). Lancet 1961; 2:1120-1122.
18. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661.
19. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in exacerbating-remitting multiple sclerosis. Ann Neurol 1996;39:285-294.
20. Simon JH, Jacobs LD, Campion M, et al. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. Ann Neurol 1996;43:79-87.
21. Rudick RA, Goodkin DE, Jacobs LD, et al. Impact of interferon beta 1-a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Neurology 1997;49:358-363.
22. PRISMS Study Group. Randomized double-blind placebo-controlled study of interferon beta-1a in relapsing-remitting multiple sclerosis. Lancet 1998;352:1498-1504.
23. Li DKB, Paty DW, UBC MS/MRI Analysis Research Group, PRISMS Study Group. MRI results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon beta-1a subcutaneously in MS. Ann Neurol 1999;46:197-206.
24. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995; 45:1268-1276.
25. Johnson KP, Brooks BR, Cohen JA, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology 1998;50:701-708.
26. Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized placebo-controlled study of the effects of glatiramer acetate on MRI measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001;49:290-297.
27. Yong VW, Chabot S, Stuve O, Williams G. Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology 1998;51:682-689.
28. Duda PW, Schimied MC, Cook SL, Krieger JI, Hafler DA. Glatiramer acetate (Copaxone): degenerate Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest 2000; 105:967-976.